The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies
Copyright © 2024 Ankunda, Katende, Oluka, Sembera, Baine, Odoch, Ejou, Kato, and The COVID-19 Immunoprofiling Team, Kaleebu and Serwanga..
Introduction: This study aimed to delineate longitudinal antibody responses to the Pfizer-BioNTech BNT162b2 COVID-19 vaccine within the Ugandan subset of the Sub-Saharan African (SSA) demographic, filling a significant gap in global datasets.
Methods: We enrolled 48 participants and collected 320 specimens over 12 months after the primary vaccination dose. A validated enzyme-linked immunosorbent assay (ELISA) was used to quantify SARS-CoV-2-specific IgG, IgM, and IgA antibody concentrations (ng/ml) and optical densities (ODs). Statistical analyses included box plots, diverging bar graphs, and the Wilcoxon test with Bonferroni correction.
Results: We noted a robust S-IgG response within 14 days of the primary vaccine dose, which was consistent with global data. There was no significant surge in S-IgG levels after the booster dose, contrasting trends in other global populations. The S-IgM response was transient and predominantly below established thresholds for this population, which reflects its typical early emergence and rapid decline. S-IgA levels rose after the initial dose then decreased after six months, aligning with the temporal patterns of mucosal immunity. Eleven breakthrough infections were noted, and all were asymptomatic, regardless of the participants' initial S-IgG serostatus, which suggests a protective effect from vaccination.
Discussion: The Pfizer-BioNTech BNT162b2 COVID-19 vaccine elicited strong S-IgG responses in the SSA demographic. The antibody dynamics distinctly differed from global data highlighting the significance of region-specific research and the necessity for customised vaccination strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 15(2024) vom: 12., Seite 1325387 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ankunda, Violet [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.03.2024 Date Revised 05.04.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2024.1325387 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369590252 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369590252 | ||
| 003 | DE-627 | ||
| 005 | 20240405233807.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240312s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2024.1325387 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM369590252 | ||
| 035 | |a (NLM)38469296 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ankunda, Violet |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.03.2024 | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Ankunda, Katende, Oluka, Sembera, Baine, Odoch, Ejou, Kato, and The COVID-19 Immunoprofiling Team, Kaleebu and Serwanga. | ||
| 520 | |a Introduction: This study aimed to delineate longitudinal antibody responses to the Pfizer-BioNTech BNT162b2 COVID-19 vaccine within the Ugandan subset of the Sub-Saharan African (SSA) demographic, filling a significant gap in global datasets | ||
| 520 | |a Methods: We enrolled 48 participants and collected 320 specimens over 12 months after the primary vaccination dose. A validated enzyme-linked immunosorbent assay (ELISA) was used to quantify SARS-CoV-2-specific IgG, IgM, and IgA antibody concentrations (ng/ml) and optical densities (ODs). Statistical analyses included box plots, diverging bar graphs, and the Wilcoxon test with Bonferroni correction | ||
| 520 | |a Results: We noted a robust S-IgG response within 14 days of the primary vaccine dose, which was consistent with global data. There was no significant surge in S-IgG levels after the booster dose, contrasting trends in other global populations. The S-IgM response was transient and predominantly below established thresholds for this population, which reflects its typical early emergence and rapid decline. S-IgA levels rose after the initial dose then decreased after six months, aligning with the temporal patterns of mucosal immunity. Eleven breakthrough infections were noted, and all were asymptomatic, regardless of the participants' initial S-IgG serostatus, which suggests a protective effect from vaccination | ||
| 520 | |a Discussion: The Pfizer-BioNTech BNT162b2 COVID-19 vaccine elicited strong S-IgG responses in the SSA demographic. The antibody dynamics distinctly differed from global data highlighting the significance of region-specific research and the necessity for customised vaccination strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a IgG IgM and IgA antibodies | |
| 650 | 4 | |a Pfizer BioNTech BNT162b2 COVID-19 vaccine | |
| 650 | 4 | |a Sub-Saharan African populations | |
| 650 | 4 | |a Ugandan population | |
| 650 | 4 | |a booster dose | |
| 650 | 4 | |a breakthrough infections | |
| 650 | 4 | |a longitudinal antibody responses | |
| 650 | 4 | |a seropositivity classification | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 700 | 1 | |a Katende, Joseph Ssebwana |e verfasserin |4 aut | |
| 700 | 1 | |a Oluka, Gerald Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Sembera, Jackson |e verfasserin |4 aut | |
| 700 | 1 | |a Baine, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Odoch, Geoffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Ejou, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Laban |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 Immunoprofiling Team |e verfasserin |4 aut | |
| 700 | 1 | |a Kaleebu, Pontiano |e verfasserin |4 aut | |
| 700 | 1 | |a Serwanga, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Akoli, Christine Hermilia |e investigator |4 oth | |
| 700 | 1 | |a Namuyanja, Angela |e investigator |4 oth | |
| 700 | 1 | |a Opio, Solomon |e investigator |4 oth | |
| 700 | 1 | |a Kalyebi, Arthur Watelo |e investigator |4 oth | |
| 700 | 1 | |a Ssali, Ivan |e investigator |4 oth | |
| 700 | 1 | |a Gombe, Ben |e investigator |4 oth | |
| 700 | 1 | |a Mugaba, Susan |e investigator |4 oth | |
| 700 | 1 | |a Nantambi, Hellen |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 15(2024) vom: 12., Seite 1325387 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g day:12 |g pages:1325387 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2024.1325387 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |b 12 |h 1325387 | ||